Critical androgen-sensitive periods of rat penis and clitoris development by Welsh, Michelle et al.
ORIGINAL ARTICLE
Critical androgen-sensitive periods of rat penis and clitoris
development
Michelle Welsh,* David J. MacLeod,* Marion Walker, Lee B. Smith and Richard M. Sharpe
MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, The Queen’s Medical Research Institute, Edinburgh, UK
Introduction
Formation of a penis is induced by androgen action in the
ﬁrst trimester of pregnancy in humans (Husmann, 2002),
and most of its subsequent growth is also androgen-depen-
dent (Husmann, 2002; Boas et al., 2006; Camurdan et al.,
2007). Therefore normal length/size of the penis depends
critically on androgens, but how and when androgens
mediate this is unclear. This is particularly true if a penis is
normally formed but abnormally small (micropenis) or is
malformed as in hypospadias (Bin-Abbas et al., 1999; Hus-
mann, 2002). Penis size amongst normal men varies con-
siderably (Ponchietti et al., 2001) and men’s anxiety about
‘normality’ of their penis size is widespread (Vardi, 2006).
Clariﬁcation of when androgens act to promote normal
penis formation and growth should therefore advance
understanding of causes of abnormal penile development/
growth and its management.
Manifestation of micropenis at birth in boys is inter-
preted as there having been deﬁcient androgen action
during late gestation (Bin-Abbas et al., 1999; Husmann,
2002; Grumbach, 2005). Boys with micropenis and some
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Summary
Androgen control of penis development/growth is unclear. In rats, androgen
action in a foetal ‘masculinisation programming window’ (MPW; e15.5–e18.5)’
predetermines penile length and hypospadias occurrence. This has implications
for humans (e.g. micropenis). Our studies aimed to establish in rats when andro-
gen action/administration affects development/growth of the penis and if deﬁcits
in MPW androgen action were rescuable postnatally. Thus, pregnant rats were
treated with ﬂutamide during the MPW ± postnatal testosterone propionate
(TP) treatment. To assess penile growth responsiveness, rats were treated with
TP in various time windows (late foetal, neonatal through early puberty, puberty
onset, or combinations thereof). Phallus length, weight, and morphology, hypo-
spadias and anogenital distance (AGD) were measured in mid-puberty (d25) or
adulthood (d90) in males and females, plus serum testosterone in adult males.
MPW ﬂutamide exposure reduced adult penile length and induced hypospadias
dose-dependently; this was not rescued by postnatal TP treatment. In normal
rats, foetal (e14.5–e21.5) TP exposure did not affect male penis size but increased
female clitoral size. In males, TP exposure from postnatal d1–24 or at puberty
(d15–24), increased penile length at d25, but not ultimately in adulthood. Foe-
tal + postnatal TP (e14–postnatal d24) increased penile size at d25 but reduced
it at d90 (due to reduced endogenous testosterone). In females, this treatment
caused the biggest increase in adult clitoral size but, unlike in males, phallus size
was unaffected by TP during puberty (d15–24). Postnatal TP treatment advanced
penile histology at d25 to more resemble adult histology. AGD strongly corre-
lated with ﬁnal penis length. It is concluded that adult penile size depends criti-
cally on androgen action during the MPW but subsequent growth depends on
later androgen exposure. Foetal and/or postnatal TP exposure does not increase
adult penile size above its ‘predetermined’ length though its growth towards this
maximum is advanced by peripubertal TP treatment.
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months with testosterone to induce penile growth. Whilst
this is generally successful (Bin-Abbas et al., 1999), a pro-
portion show a poor growth response (Husmann, 2004;
Lee & Houk, 2004; Zenaty et al., 2006) and most boys
with micropenis ultimately have a smaller than average
penis in adulthood (Husmann, 2002; Lee & Houk, 2004).
Studies in rats have also questioned whether neonatal/
infant testosterone treatment of micropenis might impair
androgen-dependent growth during puberty (Husmann &
Cain, 1994; Levy et al., 1996). Although current consensus
is that testosterone treatment does not impair later penis
growth (Sutherland et al., 1996; Baskin et al., 1997; Bin-
Abbas et al., 1999) doubts persist about optimal timing of
treatment (Lee & Houk, 2004) mainly as a result of poor
understanding of penis development.
Recent studies in rats have identiﬁed a ‘masculinisation
programming window’ (MPW) at the onset of foetal tes-
tosterone production (e15.5–e18.5), when sufﬁcient
androgen action must occur to ensure normal formation
(and subsequent development) of the penis and reproduc-
tive tract (Clark et al., 1993; Welsh et al., 2008). Subnor-
mal androgen action during the MPW may induce
hypospadias and results in a smaller than normal penis at
puberty (Welsh et al., 2008). In comparison, blocking
androgen action in late gestation may affect penile growth
(Husmann, 2002) but does not induce hypospadias
(Welsh et al., 2008). Therefore penis formation and
growth are both androgen-dependent, but are affected by
androgens in different time windows, the ‘formation win-
dow’ (MPW) being narrow, whereas the ‘growth window’
is wide. Evidence points towards a similar MPW in
humans (probably within 8–14 weeks’ gestation; Welsh et
al., 2008) and in non-human primates (Prahalada et al.,
1997; Herman et al., 2000). Androgen-dependent penile
growth occurs at three time points in humans: in late gesta-
tion (Husmann, 2002; Grumbach, 2005), the ﬁrst 4 years
after birth (Husmann, 2002; Grumbach, 2005; Boas et al.,
2006; Camurdan et al., 2007) and at puberty (Husmann,
2002). However, although androgens regulate penile
growth postnatally, androgen action during the MPW
may determine the capacity for this growth (Welsh et al.,
2008).
If androgen action within the MPW determines for-
mation of a normal penis and its size, then this implies
that subnormal androgen action during the MPW can-
not be rescued by later androgen action (Welsh et al.,
2008). This could explain the poor penile growth
response and below average adult penile size in some
boys with micropenis (Husmann, 2004; Lee & Houk,
2004; Zenaty et al., 2006); it might also explain some of
the variation in penile size amongst normal men.
Therefore, the aim of this study in rats was to establish
when androgen-dependent growth of the normal and
abnormal penis is induced and how this relates to ﬁnal
penile length.
Materials and methods
Animals and treatments
Wistar rats were maintained under standard conditions
according to UK Home Ofﬁce guidelines. Animals had
free access to water and a soy-free breeding diet (SDS;
Dundee, Scotland). Time-matings were established and
presence of a vaginal plug was deﬁned as embryonic day
0.5 (e0.5); for this study at least 3 L were used per treat-
ment group. Treatment regimes are summarised in Fig. 1.
In the ﬂutamide (Sigma-Aldrich, Poole, UK) studies,
dams were dosed daily from e15.5 to e18.5 by oral gavage
with 0, 2, 5, 10 or 100 mg/kg in 1 mL/kg corn oil/2.5%
DMSO (Sigma-Aldrich); this treatment time window
encompasses the MPW (Welsh et al., 2008).
As ﬂutamide exposure in the MPW reduces adult penile
size, we investigated if exogenous postnatal androgens
could overcome this deﬁcit. Thus, 9 ﬂutamide-exposed
(10 mg/kg) male offspring were treated postnatally from
d1 to d24 with 20 mg/kg testosterone propionate (TP;
Sigma-Aldrich) and examined on d90 (adulthood); this
treatment window for TP was selected as it was the most
effective for increasing penile growth in the controls (see
Results).
For prenatal TP treatment, pregnant dams were injected
subcutaneously with 20 mg/kg TP in 0.4 mL corn oil daily
from e14.5–e21.5. This treatment can induce dystocia
(Welsh et al., 2008) so to avoid foetal mortality and
maternal suffering, foetuses from TP-treated dams were
caesarian-derived and cross-fostered to untreated mothers
that had delivered within the previous 6 h. For postnatal
TP treatment, pups were injected subcutaneously
with 20 mg/kg TP in 0.4 mL corn oil every third day from
d1–14, d1–24 or d15–24. Some animals exposed prenatally
to TP were also treated postnatally with TP. Details of ani-
mal numbers are shown in Table 1. In one experiment,
adult male rats (d70) were treated for 10 days with 20
mg/kgTPaccordingtotheaboveregimeandexaminedond80.
Tissue recovery and penile measurements
Animals were killed on d25 or d90 by inhalation of car-
bon dioxide and cervical dislocation. Blood was collected
by cardiac puncture and plasma testosterone and luteini-
sing hormone (LH) concentrations were measured as pre-
viously published (Atanassova et al., 1999; Welsh et al.,
2008). Anogenital distance (AGD) was measured using
digital callipers (Faithfull Tools, Kent, UK) as a measure
of androgen exposure during the MPW (Welsh et al.,
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viously established criteria (Welsh et al., 2008). The phal-
lus from both sexes was dissected out, its length
measured with digital callipers and weighed, ﬁxed for 6 h
in Bouins, transferred into 70% ethanol and processed
into parafﬁn wax (Welsh et al., 2008).
Penile histology
Penis histology was examined using Goldner’s stain on
penile cross-sections from animals in each of the treatment
groups (Welsh et al., 2008). Penises from d90 animals were
decalciﬁed by incubating in neutral EDTA for 10 days at
37  C prior to sectioning/staining.
Statistical analysis
Data were analysed using graphpad prism version 5
(Graph Pad Software Inc., San Diego, CA, USA) and one-
way analysis of variance (anova) followed by the Bonfer-
roni post-test. Incidence of hypospadias was analysed
using Fisher’s exact test. Correlation between AGD and
penile length was analysed using linear regression.
Results
Prenatal androgen action determines adult penile length
in males
Treatment of pregnant females with ﬂutamide during the
MPW (e15.5–e18.5) caused a dose-dependent decrease in
adult penile length in male offspring, independent of the
occurrence of hypospadias (Fig. 2). Postnatal TP treat-
ment after foetal ﬂutamide (10 mg/kg) exposure did not
alter adult penile length (Fig. 2) in comparison with the
corresponding ﬂutamide-exposed, non-TP-treated ani-
mals (Fig. 2). Adult penile length was highly correlated
with AGD in the control and ﬂutamide-treated males
(Fig. 2).
Masculinisation
programming
window
e14 Rat
Flutamide e15.5–e18.5
Flutamide e15.5–e18.5
TP e14.5–e21.5
TP e14.5–d24
TP d1–24
TP d1–14
TP d1–24
TP d15–24
TP d70–80
e16 e18 e20 Birth Pubertal Adult
Perinatal 2
nd trimester 1
st trimester Human Pubertal Adult
Figure 1 Schematic diagram to show timings
of rat treatments in the current studies and
their relation to comparable timings in
humans. The masculinisation programming
window in rats occurs between e15.5–e18.5
and is predicted to occur in humans between
weeks 8–14.
Table 1 Numbers of animals treated during the various time windows with vehicle (controls) or with testosterone proprionate (TP) and their sam-
pling ages
Postnatal TP-treatment group
Postnatal day 25
(mid-puberty)
Postnatal day 90
(adulthood)
Adult serum testosterone
(ng/mL)
Males Females Males Females Males (day 90)
Controls (vehicle) 18 20 12 11 2.33 ± 0.45
TP e14.5–e21.5 8 7 9 3 4.10 ± 0.45
TP e14.5–d24 8 8 6 6 0.15 ± 0.02***
TP d1–d24 9 6 7 5 3.50 ± 1.75
TP d15–d24 5 5 4 5 3.70 ± 0.98
Serum levels of testosterone (means ± SEM) in males at adulthood (d90) are also shown.
***p < 0.001, in comparison with the respective control group.
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length in males
Testosterone propionate exposure in any time window
signiﬁcantly increased penile length in males at d25
compared with vehicle (Fig. 3a). This enhancement was
the smallest for foetally TP-exposed males and greatest
for those exposed postnatally from d1 to d24 (Fig. 3a).
None of these enhancements persisted into adulthood,
as TP treatment at any time failed to augment adult
penile length (Fig. 3a). Indeed, combined prena-
tal + postnatal TP treatment (e14.5–d24) resulted in
decreased ultimate adult penile length (Fig. 3a), pre-
sumably because of the subnormal endogenous testos-
terone levels in this treatment group (<10% of the
control levels; Table 1). In turn, this decrease in endo-
genous testosterone concentrations is probably explained
by abnormally low LH concentrations in this group
(controls 4.2 ± 0.06 ng/ml, n = 8; TP e14.5–d24 0.6 ±
0.09, n =6 ;p < 0.001). Testosterone levels were normal
in all other TP-treated groups (Table 1). Similar results
were found for penile weight/length (as an indirect
measure of girth) as for length (Fig. 3a) in males at
d25 and d90.
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Figure 2 Penile length (means ± SEM; top left), incidence of hypospadias (top right) and the relationship between penile length and anogenital
distance (AGD; bottom) in adult male rats that had been exposed in utero (e15.5–e18.5) to vehicle (controls) or various doses of ﬂutamide (left)
and the effects of postnatal administration of testosterone propionate (TP) from d1 to d24 (right) in a group of animals prenatally exposed to
10 mg/kg ﬂutamide. Values in the upper left panel are means ± SEM for 9–20 animals per group (overall n = 88). Solid horizontal line shows the
mean penile length for control males and the dashed horizontal line shows the mean for males exposed in utero to 10 mg/kg ﬂutamide.
**p < 0.01, ***p < 0.001, in comparison with the control group. Postnatal TP treatment had no signiﬁcant effect (NS) on penile length in
comparison with animals prenatally exposed to ﬂutamide alone.
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signiﬁcant change in penile length between d25 and d90 in
groups that included postnatal TP treatment, whereas vehi-
cle-treated controls showed a > 80% increase (p < 0.001)
in penile length over this period (Fig. 3a). This implies that
postnatal TP treatment simply advances penile growth,
rather than enhancing it. This was conﬁrmed by examina-
tion of penile morphology of the group with the greatest
advancement of penile growth at d25 (i.e. TP d1–24). This
showed normal gross morphology but with increased
penile diameter, ossiﬁcation of the os bone and separation
of the prepuce, all of which represent a precocious advance
towards the normal adult phenotype (Fig. 3b). Consistent
with this, TP administration to adult rats for 10 days did
not increase penile length (controls 11.0 ± 0.58 mm,
n = 4; TP 11.1 ± 0.27, n = 6; means ± SEM).
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Figure 3 (a) Penile length (top panels) and weight/length (lower panels) at mid-puberty (d25) or in adulthood (d90) in male rats exposed in utero
(e14.5–e21.5) or postnatally from d1 to d24 or from d15 to d24, or a combination of prenatal and postnatal exposure (e14.5–d24), to testoster-
one propionate (TP). Data are shown for vehicle-treated males (controls) and females for comparison. Solid horizontal line shows the mean penile
length for control males at d25 and the dashed horizontal line shows the mean for d90 male controls. *p < 0.05, **p < 0.01, ***p < 0.001, in
comparison with the respective control group. Values are means ± SEM for the number of animals shown in Table 1. (b) Representative penile
cross-sectional morphology in the control rats at d25 (left) and d90 (right) in comparison to a d25 rat treated postnatally from d1 to d24 with TP
(middle). In the latter, note the increased penile diameter, preputial separation (small arrows) and ossiﬁcation of the os penile bone (*blue-green
staining) in comparison with the d25 control, and its advancement towards the adult phenotype. Sections were stained with Goldners as
described elsewhere (Welsh et al., 2008). Scale bar shows 0.5 mm. U, urethra.
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females
Foetal exposure (e14.5–e21.5) of females to TP caused a
small increase in clitoral length at d25, but maximum
clitoral length occurred with combined foetal and postnatal
treatment (e14.5–d24; Fig. 4). TP treatment from d1 to 24
increased clitoral length at d25 whereas treatment from d15
to 24 caused a notably smaller increase (Fig. 4). In all TP
treatment groups, clitoral length at d90 remained compara-
ble with the length at d25 whereas the controls showed a
modest size increase from d25 to d90 (Fig. 4).
Discussion
The primary aim of these studies was to determine when
penile length and growth are determined by androgens in
the rat. This was prompted by the data from clinical studies
involving testosterone treatment of boys with micropenis
and/or hypospadias and the uncertainty over whether
the age of testosterone treatment (of micropenis) affects
treatment success in terms of penile growth. Earlier studies
by ourselves and others have demonstrated that androgen-
driven growth/elongation of the rat penis continues after
the MPW (Husmann & Cain, 1994; Levy et al., 1996;
Welsh et al., 2008), consistent with current understanding
in humans and non-human primates (Liu et al., 1991;
Brown et al., 1999; Herman et al., 2000; Husmann, 2002;
Grumbach, 2005; Boas et al., 2006). This raised the
possibility that testosterone administration to rats for a
sufﬁcient period postnatally might restore normal penile
length in foetally ﬂutamide-exposed rats or increase ulti-
mate penis size in the control animals. Such studies would
assist in management of boys with penile abnormalities.
Our results show that adult penile size in rats requires
adequate androgen action within the MPW and that deﬁ-
ciencies in androgen action at this time ‘dose-depen-
dently’ reduces penile length in adulthood, extending our
previous ﬁndings (Welsh et al., 2008). This deﬁcit cannot
be rescued by postnatal TP treatment, even though
androgens increase penile growth in the neonatal and
peripubertal periods in rats (this study; Husmann & Cain,
1994; Levy et al., 1996; Husmann, 2002). Our ﬁndings
show that postnatal testosterone treatment of rats at any
stage prior to achievement of adult penile size (Fig. 1)
will advance, but not ultimately enhance, penile size, con-
sistent with earlier ﬁndings (Levy et al., 1996). These con-
clusions derive from administration of supranormal
testosterone doses to normal animals, so extrapolation to
boys with micropenis is not straightforward. However,
similar conclusions were reached in rats in which micro-
penis had been induced prior to testosterone treatment
Figure 4 Clitoral length (top panels) and weight/length (lower panels) at mid-puberty (d25) or in adulthood (d90) in female rats exposed in utero
(e14.5–e21.5) or postnatally from d1 to d24 or from d15 to d24, or a combination of prenatal and postnatal exposure (e14.5–d24), to testoster-
one propionate (TP). Data are shown for vehicle (controls)-treated males and females for comparison. Solid horizontal line shows the mean clitoral
length for control females at d25 and the dashed horizontal line shows the mean for d90 female controls. *p < 0.05, ***p < 0.001, in compari-
son with the respective control group. Values are means ± SEM for the number of animals shown in Table 1.
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ment (this study). Androgen treatment of boys/infants
with micropenis suggests that the human penis is respon-
sive to growth stimulation by exogenous androgens at
comparable stages of development to rats (Bin-Abbas et
al., 1999; Grumbach, 2005).
Based on our ﬁndings, it is likely that ﬁnal penile
size in men depends on a sufﬁcient level of androgen
action within the MPW and that deﬁcient androgen
action at this time will have permanent and irrecover-
able consequences for ﬁnal penile size. In this regard,
boys with isolated micropenis show a bigger increase in
penile length in response to testosterone treatment than
do boys with micropenis + hypospadias (Velasquez-
Urzola et al., 1998). This ﬁts with our ﬁndings which
show that hypospadias in rats arises as a result of the
deﬁcient androgen action only within the MPW (Welsh
et al., 2008) and such males have reduced adult penile
length and growth capacity (this study). This being the
case, an important question is can penile growth capac-
ity be predicted at birth? Our studies show that AGD
in adulthood (this study) and in puberty (Welsh et al.,
2008) correlate highly with penile length, consistent
with both being determined by androgen action within
the MPW (Welsh et al., 2008). Distinctive differences in
male–female AGD are evident at birth in humans
(Swan et al., 2005; Swan, 2008) as in rats (McIntyre et
al., 2001), and reduced AGD is associated with hypo-
spadias in both (Hsieh et al., 2008; Welsh et al., 2008).
Therefore, measuring AGD at birth may predict the
growth capability and adult size of the penis in humans
because AGD at birth and adulthood are highly corre-
lated in rats (McIntyre et al., 2001) and adult AGD is
related to ﬁnal penile length (this study). Two studies
have reported a positive relationship between AGD
(corrected for bodyweight) and penis size/length in
infant boys (Swan et al., 2005; Swan, 2008) whereas
another study found no correlation (Romano-Riquer et
al., 2007), although this study did not correct AGD for
bodyweight, an important confounder in babies (Swan,
2008).
The previous studies (Jacobs et al., 1977; Levy et al.,
1996) showed that testosterone administered to rats
peripubertally or in adulthood in similar/higher doses to
those used in these studies, did not enhance adult penile
size. Our ﬁndings, involving testosterone exposure in a
wider range of time-windows, conﬁrm this. Moreover,
foetal androgen exposure during or during and after the
MPW (Welsh et al., 2008) does not enhance ultimate
penile size, showing that unknown non-androgenic fac-
tors must predetermine the maximum size to which the
penis can grow (‘penile potential’). We suggest that this
is the ﬁrst of three stages in penis development. Andro-
gen action is essential to achieve this potential, most
critically within the MPW (stage 2), but also in late foe-
tal life and postnatally when growth of the penis to its
predetermined level depends on sufﬁcient androgen
stimulation (stage 3). In normal animals, testosterone
levels in foetal and postnatal life are sufﬁcient to com-
plete stages 2 and 3. Deﬁciencies in androgen action in
stage 3 are potentially recoverable by later androgen
treatment, whereas deﬁciencies in stage 2 are not. Our
data (based on androgen action) also suggests that ﬁnal
penile size cannot be increased therapeutically in normal
males.
Earlier rat studies suggested that testosterone treatment
in some postnatal periods might be detrimental to ﬁnal
penis size (Husmann & Cain, 1994; Levy et al., 1996;
Husmann, 2002). Our study shows that TP treatment
spanning birth (foetal + postnatal) led to signiﬁcantly
reduced penile size in adulthood, whereas TP treatment
either foetally or postnatally did not have this effect.
These ﬁndings can be explained by the near baseline levels
of testosterone found in adulthood in the foetal +
postnatal TP-treatment group, because of grossly
suppressed LH levels, indicating failure to establish a
normally functioning hypothalamic–pituitary–testicular
axis. The latter is programmed around birth in rats
(Handa et al., 1985) and has presumably been disrupted
by the exogenous androgen exposure. This further illus-
trates the importance of endogenous androgens for the
adult penis to grow to its predetermined length.
The effect of testosterone exposure on clitoral develop-
ment in females was investigated as a comparison to
males. Our results show that clitoral growth in females
remains androgen-responsive after birth, but for a more
restricted period than the penis in males, as unlike males
there was little responsiveness to TP at d15–24. In human
females, the clitoris is androgen growth-responsive
foetally and postnatally (Sane & Pescovitz, 1992) and even
in adulthood (Slayden, 1998; Gooren & Giltay, 2008),
perhaps suggesting some difference from rats. An interest-
ing observation from this study is that TP treatment from
d1 to 24 induced a substantial increase in clitoral size that
was maintained through to adulthood despite the cessa-
tion of TP treatment after d24. Combined foetal and
postnatal (d1–24) androgen exposure caused an even lar-
ger, permanent increase in clitoral size.
In conclusion, we show that adult penile size in rats is
critically dependent on exposure to sufﬁcient androgen
action during the foetal MPW. Deﬁciencies in androgen
action in the MPW are irrecoverable by postnatal andro-
gen treatment, even though the penis remains androgen
growth-responsive postnatally. Assuming the same applies
to humans, it may explain the limited growth of the penis
that occurs after androgen treatment of some boys with
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ﬁnal penile length in rats, penile growth responsiveness
may be predictable by measuring AGD of boys at birth.
Finally, additional androgen exposure at any age in rats
cannot enhance ultimate penile length, although it can
advance growth postnatally towards its predetermined
maximum. The latter is determined in utero by unknown
androgen-independent factors, but sufﬁcient androgen
action (in the right time windows) is necessary to achieve
this potential.
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